Results 21 to 30 of about 6,312 (217)
Hallmarks of response to immune checkpoint blockade [PDF]
Unprecedented advances have been made in the treatment of cancer through the use of immune checkpoint blockade, with approval of several checkpoint blockade regimens spanning multiple cancer types. However, responses to this form of therapy are not universal, and insights are clearly needed to identify optimal biomarkers of response and to combat ...
Cogdill, Alexandria P +2 more
openaire +2 more sources
Advances in cancer immunity have promoted a major breakthrough in the field of cancer therapy. This is mainly associated with the successful development of immune checkpoint inhibitors (ICIs) for multiple types of human tumors.
Yuxiao Song +5 more
doaj +1 more source
Metabolic Implications of Immune Checkpoint Proteins in Cancer
Expression of immune checkpoint proteins restrict immunosurveillance in the tumor microenvironment; thus, FDA-approved checkpoint inhibitor drugs, specifically PD-1/PD-L1 and CTLA-4 inhibitors, promote a cytotoxic antitumor immune response.
Elizabeth R. Stirling +5 more
doaj +1 more source
Mechanisms of Resistance to Immune Checkpoint Blockade [PDF]
The recent development of effective immune checkpoint inhibition (ICI), first demonstrated in melanoma, has revolutionized cancer treatment. Monoclonal antibodies blocking the immune checkpoints cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed death 1 receptor (PD-1) have shown substantial clinical benefit in a subset of patients ...
David, Liu +2 more
openaire +2 more sources
Synergistic immunotherapy of glioblastoma by dual targeting of IL-6 and CD40
Glioblastomas are generally resistant to treatment with immune checkpoint inhibitors. Here the authors show that IL6 blockade, in combination with a CD40 agonist, overcomes macrophage-mediated immunosuppression and sensitizes glioblastoma to immune ...
Fan Yang +17 more
doaj +1 more source
Immune Checkpoint Blockade in Cancer Therapy [PDF]
Immunologic checkpoint blockade with antibodies that target cytotoxic T lymphocyte–associated antigen 4 (CTLA-4) and the programmed cell death protein 1 pathway (PD-1/PD-L1) have demonstrated promise in a variety of malignancies. Ipilimumab (CTLA-4) and pembrolizumab (PD-1) are approved by the US Food and Drug Administration for the treatment of ...
Michael A, Postow +2 more
openaire +2 more sources
PD-1 and LAG-3 Checkpoint Blockade: Potential Avenues for Therapy in B-Cell Lymphoma
The dependence of cancer on an immunotolerant tumor microenvironment (TME) is well established. Immunotherapies that overcome tumor-induced immune suppression have been central to recent advancements in oncology.
Joshua W. D. Tobin +3 more
doaj +1 more source
Immune checkpoint inhibitors, which target coinhibitory T cell molecules to promote anticancer immune responses, are on the rise to become a new pillar of cancer therapy.
Carmen Stecher +7 more
doaj +1 more source
Immune checkpoint blockade represents the latest revolution in cancer treatment by substantially increasing patients’ lifetime and quality of life in multiple neoplastic pathologies.
Chiara Ursino +4 more
doaj +1 more source
Immune checkpoint blockade in lymphoid malignancies [PDF]
Malignant cells may subvert and escape endogenous host immune surveillance by up‐regulation of immune inhibitory signals known as immune checkpoints. These checkpoints are important therapeutic targets, and antibodies that block checkpoint signaling have shown remarkable efficacy in some solid tumors as well as in some refractory hematologic ...
Gita, Thanarajasingam +2 more
openaire +2 more sources

